% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Paisana:276213,
      author       = {E. Paisana and R. Cascão and C. Custódia and N. Qin$^*$
                      and D. Picard$^*$ and D. Pauck$^*$ and T. Carvalho and P.
                      Ruivo and C. Barreto and D. Doutel and J. Cabeçadas and R.
                      Roque and J. Pimentel and J. Miguéns and M. Remke$^*$ and
                      J. T. Barata and C. C. Faria},
      title        = {{UBE}2{C} promotes leptomeningeal dissemination and is a
                      therapeutic target in brain metastatic disease.},
      journal      = {Neuro-oncology advances},
      volume       = {5},
      number       = {1},
      issn         = {2632-2498},
      address      = {Oxford},
      publisher    = {Oxford University Press},
      reportid     = {DKFZ-2023-01025},
      pages        = {vdad048},
      year         = {2023},
      abstract     = {Despite current improvements in systemic cancer treatment,
                      brain metastases (BM) remain incurable, and there is an
                      unmet clinical need for effective targeted therapies.Here,
                      we sought common molecular events in brain metastatic
                      disease. RNA sequencing of thirty human BM identified the
                      upregulation of UBE2C, a gene that ensures the correct
                      transition from metaphase to anaphase, across different
                      primary tumor origins.Tissue microarray analysis of an
                      independent BM patient cohort revealed that high expression
                      of UBE2C was associated with decreased survival.
                      UBE2C-driven orthotopic mouse models developed extensive
                      leptomeningeal dissemination, likely due to increased
                      migration and invasion. Early cancer treatment with
                      dactolisib (dual PI3K/mTOR inhibitor) prevented the
                      development of UBE2C-induced leptomeningeal metastases.Our
                      findings reveal UBE2C as a key player in the development of
                      metastatic brain disease and highlight PI3K/mTOR inhibition
                      as a promising anticancer therapy to prevent late-stage
                      metastatic brain cancer.},
      keywords     = {PI3K/mTOR inhibition (Other) / UBE2C (Other) / brain
                      metastases (Other) / leptomeningeal dissemination (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37215954},
      pmc          = {pmc:PMC10195208},
      doi          = {10.1093/noajnl/vdad048},
      url          = {https://inrepo02.dkfz.de/record/276213},
}